Moderna begins late-stage bird flu shot trial in U.S. and UK

Moderna has initiated a Phase 3 study for its investigational H5 pandemic influenza mRNA vaccine candidate, mRNA-1018, in the U.S. and UK, aiming to enroll approximately 4,000 adults. This trial is supported by CEPI with up to $54.3 million in funding and is a crucial step in global pandemic preparedness efforts. If successful, positive data from this trial, alongside Moderna’s seasonal flu candidate mRNA-1010, will support global regulatory submissions, with Moderna committing 20% of its H5 manufacturing capacity for low- and middle-income countries.